Search

Displaying results 2951 - 2960 of 10000 in total
  1. Drug

    MGN-4893

    go.drugbank.com/drugs/DB17338
    Experimental

    MGN-4893 is an inhibitor of microRNA-451. In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.[L47356]

    Synonyms: MGN 4893
  2. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    [A242572] On November 29, 2021, the FDA approved pafolacianine as an adjunct imaging agent for intraoperative identification of malignant lesions in adult patients with ovarian cancer. … Pafolacianine targets the folate receptor alpha (FRα) which is upregulated in numerous epithelial malignancies.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Bordetella pertussis fimbriae 2/3 antigen

    go.drugbank.com/drugs/DB10790
    ApprovedInvestigational

    Bordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct fimbriae (Fim2 and Fim3).

    Mixtures: ADACEL 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇEREN FLAKON, 5 ADET, ADACEL 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇEREN FLAKON, 1 ADET
  4. Drug

    Bfpet F-18

    go.drugbank.com/drugs/DB15424
    Investigational

    Bfpet F-18 is under investigation in clinical trial NCT03265431 (Evaluation of PET/MR in Patients Selected for Ablation Therapy).

  5. Drug

    MK-0752

    go.drugbank.com/drugs/DB12852
    Investigational

    Mk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer).

  6. Drug

    GVAX

    go.drugbank.com/drugs/DB17276
    Investigational

    GVAX is a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transfected tumor cell vaccine.

    Synonyms: Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines, Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines
  7. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults.

  8. Drug

    Imetelstat

    go.drugbank.com/drugs/DB14909
    ApprovedInvestigational

    [erythropoietin]), but primary resistance to these agents is frequent - the median response duration is 18 to 24 months, with most responders (70%) relapsing due to loss of sensitivity of erythroid progenitors … [A187838] Imetelstat received FDA approval in June 2024 for use in certain patients with MDS who have transfusion-dependent anemia and are unable to use ESAs.[L50883,L50888]

  9. Drug

    Adavosertib

    go.drugbank.com/drugs/DB11740
    Investigational

    MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

  10. Drug

    OM85

    go.drugbank.com/drugs/DB16533
    Investigational

    OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity.

    Categories: Complex MixturesSynonyms: OM-85, OM 85 BV